Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process

Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process

The addition of durvalumab consolidation to concurrent chemoradiation therapy (cCRT) has fundamentally changed the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC). Nevertheless, concerns related to esophagitis and pneumonitis potentially impact the broad...

Full description

Bibliographic Details
Main Authors: Anthony M. Brade, Houda Bahig, Andrea Bezjak, Rosalyn A. Juergens, Charmaine Lynden, Nicolas Marcoux, Barbara Melosky, Devin Schellenberg, Stephanie Snow
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Current Oncology
Subjects:
lung cancer
concurrent chemoradiation therapy
immuno-oncology
esophagitis
pneumonitis
durvalumab
Online Access:https://www.mdpi.com/1718-7729/31/11/483

Internet

https://www.mdpi.com/1718-7729/31/11/483

Similar Items